AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
Leukemia & Lymphoma Society worked with US FDA on umbrella trial strategy to accelerate development of new targeted therapies in molecularly-defined subsets of AML.
You may also be interested in...
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.
Basket trials are building a path for tissue-agnostic drug development in oncology, and plans are proceeding for more master protocols in pediatric cancers, acute myeloid leukemia and pancreatic cancer.